CHRISTINE CALABRESE: Open Payments
NPI 1487630232 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,675 in 83 payments from 16 companies in 2025. Trend: 2023 $718 · 2024 $1,021 · 2025 $1,675
Food & beverage: $1,675
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $416 |
| Ardelyx, Inc. | 21 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $166 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| QOL Medical, LLC | 4 | $124 |
| Madrigal Pharmaceuticals | 3 | $92 |
| Lilly USA, LLC | 3 | $81 |
| Janssen Biotech, Inc. | 3 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $55 |
| VIVUS LLC | 2 | $42 |
Products named: IBSRELA, LINZESS, RINVOQ, ZENPEP, Sucraid, ENTYVIO, REZDIFFRA, TREMFYA.
Industry payments across CT — which companies pay providers there.
